New Delhi, April 1 – The Controller General of Drugs in India has increased regulatory scrutiny against the unauthorized sale and promotion of drugs for type 2 diabetes, also known as GLP-1 drugs, the government said on Wednesday.In recent weeks, 49 businesses across the country, including...
cardiology
diabetes
drug marketing
drug regulation
drug sales
endocrinologists
glp-1 drugs
glucagon-like peptide-1 receptor agonists
india
internal medicine
medical specialties
pharmaceuticals
prescription drugs
regulatory inspections
type 2 diabetes
weight loss
The Drugs Controller of India has intensified regulatory oversight against the unauthorized sale and promotion of GLP-1-based weight loss drugs. This move comes amid growing concerns over the increasing availability of multiple generic versions of these drugs in the Indian market, through retail...
adverse effects
cardiologists
drug promotion
drug sales
drugs controller of india
endocrinologists
glp-1 drugs
healthcare regulation
india
internal medicine specialists
medical supervision
pharmaceutical supply chain
prescription drugs
regulatory oversight
weight loss drugs